ReviewFrontiers of medicine2017
Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment.
Review in Frontiers of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Improvement of Renal Function After Bariatric Surgery: a Systematic Review and Meta-analysis.Obesity surgery · 2021Pooled it
- Association of CBC‑derived inflammation indices with prevalent CKD: a cross‑sectional analysis of a Chinese data set and NHANES.Annals of medicine · 2026Article
- Mechanisms of Obesity-Related Kidney Disease: From Adipose Depot Biology to the Chymase-Aldosterone and Ghrelin-Leptin Axes.Biomolecules · 2026Review
- Obesity-related glomerulopathy, A growing kidney burden in the obesity pandemic.Clinical and experimental nephrology · 2026Review
- Novel Therapeutic Strategies for Obesity-Related Glomerulopathy.Current hypertension reports · 2025Review
- Obesity Promotes Renal Inflammation and Fibrosis Independent of Sex in SS Leptin Receptor Mutant (SSBiomedicines · 2025Article
- Rhein attenuates obesity-related glomerulopathy by inhibiting the P2X7R/NLRP3 inflammasome pathway and protecting podocytes.Iranian journal of basic medical sciences · 2025Article
- Role of metabolic conditions in cardiorenal diseases: initiating pathways and therapeutic targeting.Frontiers in nutrition · 2025Review
- Relationship Between Body Roundness Index and Diabetic Kidney Disease in Patients With Type 2 Diabetes Mellitus: A Population-Based Study.Journal of diabetes research · 2025Article
- The global incidence rate of type 2 diabetes related chronic kidney disease and predictions by Bayesian age-period-cohort analysis: findings from the Global Burden of Disease Study 2019.Frontiers in endocrinology · 2025Article
- Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway.Renal failure · 2024Article
- ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases.Journal of the American Society of Nephrology : JASN · 2024Article
- Clinical characteristics and treatment compounds of obesity-related kidney injury.World journal of diabetes · 2024Review
- Kidney and liver fat accumulation: from imaging to clinical consequences.Journal of nephrology · 2024Article
- The impact of weight loss on renal function in individuals with obesity and type 2 diabetes: a comprehensive review.Frontiers in endocrinology · 2024Review
- Management of traditional risk factors for the development and progression of chronic kidney disease.Clinical kidney journal · 2023Review
- Targeting Renal Proximal Tubule Cells in Obesity-Related Glomerulopathy.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Folate Deficiency Enhanced Inflammation and Exacerbated Renal Fibrosis in High-Fat High-Fructose Diet-Fed Mice.Nutrients · 2023Article
- Anti-obesity effects of Camellia (Camellia oleifera Abel) oil treatment on high-fat diet-induced obesity in C57BL/6J mice.Physical activity and nutrition · 2023Article
- The Potential of Cylindromatosis (CYLD) as a Therapeutic Target in Oxidative Stress-Associated Pathologies: A Comprehensive Evaluation.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In light of the rapid increase in the number of obesity incidences worldwide, obesity has become an independent risk factor for chronic kidney disease. Obesity-related glomerulopathy (ORG) is characterized by glomerulomegaly in the presence or absence of focal and segmental glomerulosclerosis lesions. IgM and complement 3 (C3) nonspecifically deposit in lesions without immune-complex-type deposits during ORG immunofluorescence. ORG-associated glomerulomegaly and focal and segmental glomerulosclerosis can superimpose on other renal pathologies. The mechanisms under ORG are complex, especially hemodynamic changes, inflammation, oxidative stress, apoptosis, and reduced functioning nephrons. These mechanisms synergize with obesity to induce end-stage renal disease. A slow increase of subnephrotic proteinuria ( < 3.5 g/d) is the most common clinical manifestation of ORG. Several treatment methods for ORG have been developed. Of these methods, renin-angiotensin-aldosterone system blockade and weight loss are proven effective. Targeting mitochondria may offer a novel strategy for ORG therapy. Nevertheless, more research is needed to further understand ORG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.